Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab +/- SD-101 with SBRT and ADT in Hormone-Naive Oligometastatic Prostate Cancer
NCT03007732Phase 2Completed
- Start
- May 2017
- Primary completion
- Mar 2025
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of nelitolimod in prostate cancer (PCa). Started May 2017; status: completed.
02
Drugs
nelitolimod
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03007732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007732.